Streptozotocin selectively injures pancreatic beta cells because these cells take it up through glucose transporter 2. Inside the cells, the compound promotes DNA alkylation, meaning chemical damage to DNA, and increases oxidative stress. The combined injury reduces beta-cell function and insulin production, creating the insulin-deficient state needed for diabetes-focused investigations.
These variables help determine how severe the induced diabetes becomes. Changes in dose or in the conditions used to administer streptozotocin can alter the extent of beta-cell injury, the resulting reduction in insulin production, and the degree of hyperglycemia. Researchers therefore need to interpret experimental findings in light of how the model was established.
Selective damage to pancreatic beta cells makes insulin deficiency a central feature of this model, allowing investigators to connect reduced insulin production with hyperglycemia. That focused biological change supports studies of diabetes-related mechanisms and treatments. It also means the model emphasizes beta-cell injury and may not represent every process contributing to diabetes in humans.
In preclinical medicine, investigators use the model to evaluate glucose-lowering therapies against an experimentally induced state of hyperglycemia and insulin deficiency. It can also support investigation of diabetes pathophysiology, meaning the biological processes underlying disease. Results may indicate whether an intervention changes disease-related metabolic features before broader therapeutic conclusions are considered.
The model extends beyond blood-glucose research by supporting studies of diabetic complications in multiple organ systems. The kidneys, nerves, and blood vessels are specifically relevant targets. Investigators can therefore examine how diabetes-associated injury affects these tissues and assess mechanisms or treatments directed at complications, rather than focusing only on hyperglycemia.
Although its reproducibility makes comparisons across experiments useful, the induced disease does not fully reproduce human diabetes. Conclusions therefore apply most directly to features created by streptozotocin, including beta-cell injury, insulin deficiency, and hyperglycemia. Translation to human disease requires careful consideration rather than assuming that experimental outcomes automatically represent clinical diabetes.